Treatment and prevention of mental disorders in low-income and middle-income countries.
We review the evidence on effectiveness of interventions for the treatment and prevention of selected mental disorders in low-income and middle-income countries. Depression can be treated effectively in such countries with low-cost antidepressants or with psychological interventions (such as cognitive-behaviour therapy and interpersonal therapies). Stepped-care and collaborative models provide a framework for integration of drug and psychological treatments and help to improve rates of adherence to treatment. First-generation antipsychotic drugs are effective and cost effective for the treatment of schizophrenia; their benefits can be enhanced by psychosocial treatments, such as community-based models of care. Brief interventions delivered by primary-care professionals are effective for management of hazardous alcohol use, and pharmacological and psychosocial interventions have some benefits for people with alcohol dependence. Policies designed to reduce consumption, such as increased taxes and other control strategies, can reduce the population burden of alcohol abuse. Evidence about the efficacy of interventions for developmental disabilities is inadequate, but community-based rehabilitation models provide a low-cost, integrative framework for care of children and adults with chronic mental disabilities. Evidence for mental health interventions for people who are exposed to conflict and other disasters is still weak-especially for interventions in the midst of emergencies. Some trials of interventions for prevention of depression and developmental delays in low-income and middle-income countries show beneficial effects. Interventions for depression, delivered in primary care, are as cost effective as antiretroviral drugs for HIV/AIDS. The process and effectiveness of scaling up mental health interventions has not been adequately assessed. Such research is needed to inform the continuing process of service reform and innovation. However, we recommend that policymakers should act on the available evidence to scale up effective and cost-effective treatments and preventive interventions for mental disorders.
Patel
Vikram
V
Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK. Vikram.patel@lshtm.ac.uk
Araya
Ricardo
R
Chatterjee
Sudipto
S
Chisholm
Dan
D
Cohen
Alex
A
De Silva
Mary
M
Hosman
Clemens
C
McGuire
Hugh
H
Rojas
Graciela
G
van Ommeren
Mark
M
D000928:Antidepressive Agents / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D007182:Income; D008297:Male; D001523:Mental Disorders / Q000145:classification / Q000517:prevention & control / Q000628:therapy; D008605:Mental Health Services / Q000191:economics / Q000706:statistics & numerical data; D011314:Preventive Health Services / Q000458:organization & administration / Q000706:statistics & numerical data*; D011614:Psychotherapy, Brief / Q000706:statistics & numerical data*; D016032:Randomized Controlled Trials as Topic / Q000191:economics / Q000706:statistics & numerical data